Adamis Pharmaceuticals has announced that the US and Japanese patent offices have approved applications for patents related to the Taper dry powder inhaler, an API-only device that was developed initially by 3M Drug Delivery Systems. Adamis acquired the device from 3M DDS in 2013.
US Patent Application No. 13/320,762 and Japanese Patent Application No. 2012-511965, which describe how the Taper functions, were submitted prior to Adamis’s acquisition of the DPI.
The company says that it plans to develop a generic fluticasone/salmeterol combination inhaler called APC-5000 DPI based on the Taper device. After successful completion of clinical trials, Adamis would submit a 505(b)(2) NDA for that product, which the company would market in the US as an alternative to GSK’s Advair Diskus. Adamis also says that it will “identify potential opportunities to market APC-5000 DPI based products” outside the US.
According to the company’s website, APC-5000 is currently in Phase 2 development. Adamis is also developing oral and nasal steroid HFA MDIs for the treatment of asthma/COPD and allergic rhinitis respectively. Both of those products are also in Phase 2 development.
Read the Adamis press release.
